Success Metrics

Clinical Success Rate
50.0%

Based on 2 completed trials

Completion Rate
50%(2/4)
Active Trials
0(0%)
Results Posted
200%(4 trials)
Terminated
2(50%)

Phase Distribution

Ph phase_2
4
100%

Phase Distribution

0

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
4(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(2)
Terminated(2)

Detailed Status

Completed2
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 24 (100.0%)

Trials by Status

completed250%
terminated250%

Recent Activity

0 active trials
Showing 4 of 4
terminatedphase_2

Randomized Phase II Adjuvant Chemotherapy ± FANG™ in Colorectal Carcinoma With Liver Metastases

NCT01505166
completedphase_2

Salvage Ovarian FANG™ Vaccine + Bevacizumab

NCT01551745
completedphase_2

Salvage Ovarian FANG™ Vaccine + Carboplatinum

NCT01867086
terminatedphase_2

Phase II FANG™ in Advanced Melanoma

NCT01453361

Clinical Trials (4)

Showing 4 of 4 trials
NCT01505166Phase 2

Randomized Phase II Adjuvant Chemotherapy ± FANG™ in Colorectal Carcinoma With Liver Metastases

Terminated
NCT01551745Phase 2

Salvage Ovarian FANG™ Vaccine + Bevacizumab

Completed
NCT01867086Phase 2

Salvage Ovarian FANG™ Vaccine + Carboplatinum

Completed
NCT01453361Phase 2

Phase II FANG™ in Advanced Melanoma

Terminated

All 4 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
4